{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Modified+Cell+Therapy&page=4", "query": { "intervention": "Gene-Modified Cell Therapy", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 141, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Modified+Cell+Therapy&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Modified+Cell+Therapy&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T15:43:51.335Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04145037", "title": "Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gaucher Disease" ], "interventions": [ { "name": "AVR-RD-02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVROBIO", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 8, "start_date": "2019-05-30", "completion_date": "2023-08-21", "has_results": true, "last_update_posted_date": "2024-01-18", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 4, "location_summary": "San Diego, California • Iowa City, Iowa • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04145037" }, { "nct_id": "NCT02414165", "title": "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Toca 511", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 403, "start_date": "2015-11-30", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414165" }, { "nct_id": "NCT00131560", "title": "Safety and Efficacy of T Cell Genetic Immunotherapy for HIV", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "VRX496-Modified Autologous T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "VIRxSYS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2005-07", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 5, "location_summary": "Palo Alto, California • Norwalk, Connecticut • Miami, Florida + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131560" }, { "nct_id": "NCT04406272", "title": "VB-111 in Surgically Accessible Recurrent/Progressive GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "VB11", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-08-01", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04406272" }, { "nct_id": "NCT01875237", "title": "Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myeloma", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Stem Cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mini Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "PROCEDURE" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2013-12-27", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875237" }, { "nct_id": "NCT00078520", "title": "Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Leukemia, B-Cell, Chronic" ], "interventions": [ { "name": "Dose Level 1", "type": "BIOLOGICAL" }, { "name": "Dose Level 2", "type": "BIOLOGICAL" }, { "name": "Dose Level 2- Fixed Dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2003-01", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078520" }, { "nct_id": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "RP3", "type": "BIOLOGICAL" }, { "name": "CCRT(concurrent chemoradiation therapy)", "type": "OTHER" }, { "name": "carboplatin and paclitaxel", "type": "OTHER" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-30", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743270" }, { "nct_id": "NCT03435796", "title": "Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Gene-modified (GM) T cell therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1541, "start_date": "2018-07-19", "completion_date": "2043-05-29", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 103, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435796" }, { "nct_id": "NCT01013415", "title": "CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infections" ], "interventions": [ { "name": "HAART", "type": "DRUG" }, { "name": "T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 17, "start_date": "2001-09", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2022-08-19", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013415" }, { "nct_id": "NCT06925542", "title": "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SLE (Systemic Lupus)", "Lupus Erythematosus, Systemic", "Lupus Nephritis", "Systemic Sclerosis", "Inflammatory Myopathy, Idiopathic", "Myositis", "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "CTX112", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CRISPR Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2025-03-10", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-11T15:43:51.335Z", "location_count": 9, "location_summary": "La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06925542" } ] }